T-Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 Trial – Lymphoma News Today
Lymphoma News Today |
T–Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 Trial
Lymphoma News Today JCAR017 is a chimeric antigen receptor (CAR) T-cell product that specifically targets CD19, a protein expressed on the surface of many different B-cell malignancies. When the engineered T-cells interact with the target protein on the cancer cell it … |
